Please provide your email address to receive an email when new articles are posted on . The average health care cost per patient in the indwelling pleural catheter (IPC) group was $40,179 vs. $46,640 ...

IT is the unfortunate lot of some patients dying of metastatic cancer of the breast, lung, cervix and so forth to be plagued by severe dyspnea due to recurrent malignant pleural effusions. Many of ...

A retrospective cohort of adults hospitalized for MPE from 2009 to 2011 was analyzed using an administrative database. The primary outcome was all-cause 30-day readmission rate. Hierarchic ...

Lung cancer patients are particularly susceptible to malignant pleural effusion, when fluid collects in the space between the lungs and the chest wall. Researchers have discovered a novel mechanism ...

A phase I/II, open label trial of Lewis Y specific monoclonal antibody IGN311 to evaluate safety and efficacy in patients with malignant effusion This is an ASCO Meeting Abstract from the 2006 ASCO ...

Researchers at Wake Forest School of Medicine have discovered that a nanoparticle therapeutic enhances cancer immunotherapy and is a possible new approach in treating malignant pleural effusion (MPE).

The scientists were able to identify and maintain cancer stem cells, as reported in PLoS One. Malignant pleural effusions may be useful as a model to study lung cancer progression and lung cancer stem ...

Cryopreserved cell-free PE fluid from 101 NSCLC patients, 8 mesothelioma and 13 with benign PE was assayed for a panel of 40 cytokines/chemokines using the Luminex system. Comparing NSCLC PE and ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window For the ...

The potential role of vascular endothelial growth factor in malignant as well as nonmalignant pleural effusion 1,2 prompted us to use bevacizumab, a monoclonal antibody against vascular endothelial ...